Binds Bacterium Or Component Thereof Or Substance Produced By Said Bacterium Patents (Class 424/164.1)
-
Publication number: 20120282268Abstract: The present invention relates to enterococcal cell wall components and their uses in the prevention and therapy of bacterial infection.Type: ApplicationFiled: January 19, 2010Publication date: November 8, 2012Inventors: Johannes Hübner, Christian Theilacker, Otto Holst, Zbigniew Kaczynski
-
Publication number: 20120237605Abstract: The present invention provides nanoparticles including a metallic core having a length along each axis of from 1 to 100 nanometers and a coating disposed on at least part of the surface of the metallic core, wherein the coating comprises polydopamine, along with methods for making and using such nanoparticles. The metallic core may be gold, silver or iron oxide and the polydopamine coating may have other substances bound to it, such as silver, targeting ligands or antibodies, or other therapeutic or imaging contrast agents. The disclosed nanoparticles can be targeted to cells for treating cancer or bacterial infections, and for use in diagnostic imaging.Type: ApplicationFiled: March 14, 2012Publication date: September 20, 2012Inventors: Phillip B. Messersmith, Kvar C.L. Black, IV, Ji Yi, Jose G. Rivera
-
Patent number: 8263747Abstract: This invention provides antibodies that specifically bind to and neutralize botulinum neurotoxin type A (BoNT/A) and the epitopes bound by those antibodies. The antibodies and derivatives thereof and/or other antibodies that specifically bind to the neutralizing epitopes provided herein can be used to neutralize botulinum neurotoxin and are therefore also useful in the treatment of botulism.Type: GrantFiled: January 13, 2009Date of Patent: September 11, 2012Assignee: The Regents of the University of CaliforniaInventors: James D. Marks, Peter Amersdorfer, Ali Razai
-
Patent number: 8241857Abstract: To provide an immunological detection method which can detect or quantify a pneumococcal antigen in a sample derived from a living body conveniently, rapidly, and with high sensitivity, and an antibody for use in the method. The present invention provides an antibody which specifically recognizes a pneumococcal F-antigen; a method for detecting or quantitating a pneumococcal antigen, characterized in that the method detects or quantitates a pneumococcal F-antigen in a sample derived from a living body through immunological assay employing the antibody; and a kit for detecting a pneumococcal antigen, the kit containing the antibody.Type: GrantFiled: March 31, 2009Date of Patent: August 14, 2012Assignee: Otsuka Pharmaceutical Co., Ltd.Inventors: Suguru Akamatsu, Yoko Saijo
-
Publication number: 20120201833Abstract: The present invention relates to peptides, particularly human monoclonal antibodies, that bind specifically to poly-N-acetyl glucosamine (PNAG), such as Staphylococcal PNAG, in acetylated, partially acetylated and/or fully deacetylated form. The invention further provides methods for using these peptides in the diagnosis, prophylaxis and therapy of infections by bacteria that express PNAG such as but not limited to Staphylococci and E. coli. Some antibodies of the invention enhance opsonophagocytic killing and in vivo protection against bacteria that express PNAG such as but not limited to Staphylococci and E. coli. Compositions of these peptides, including pharmaceutical compositions, are also provided, as are functionally equivalent variants of such peptides.Type: ApplicationFiled: December 22, 2011Publication date: August 9, 2012Applicants: BETH ISRAEL DEACONESS MEDICAL CENTER, INC., THE BRIGHAM AND WOMEN'S HOSPITAL, INC.Inventors: Gerald B. Pier, Casie Anne Kelly-Quintos, Lisa Cavacini, Marshall R. Posner
-
Publication number: 20120201834Abstract: The present invention relates to peptides, particularly human monoclonal antibodies, that bind specifically to poly-N-acetyl glucosamine (PNAG), such as Staphylococcal PNAG, in acetylated, partially acetylated and/or fully deacetylated form. The invention further provides methods for using these peptides in the diagnosis, prophylaxis and therapy of infections by bacteria that express PNAG such as but not limited to Staphylococci and E. coli. Some antibodies of the invention enhance opsonophagocytic killing and in vivo protection against bacteria that express PNAG such as but not limited to Staphylococci and E. coli. Compositions of these peptides, including pharmaceutical compositions, are also provided, as are functionally equivalent variants of such peptides.Type: ApplicationFiled: December 22, 2011Publication date: August 9, 2012Applicants: BETH ISRAEL DEACONESS MEDICAL CENTER, INC., THE BRIGHAM AND WOMEN'S HOSPITAL, INC.Inventors: Gerald B. Pier, Casie Anne Kelly-Quintos, Lisa Cavacini, Marshall R. Posner
-
Publication number: 20120195898Abstract: The present invention provides compositions including siderophore receptor polypeptides and porins from gram negative microbes, and preferably, lipopolysaccarhide at a concentration of no greater than about 10.0 endotoxin units per milliliter. The present invention also provides methods of making and methods of using such compositions.Type: ApplicationFiled: January 31, 2012Publication date: August 2, 2012Applicant: Epitopix, LLCInventors: Daryll A. Emery, Darren E. Straub
-
Publication number: 20120195899Abstract: The present invention provides compositions including siderophore receptor polypeptides and porins from gram negative microbes, and preferably, lipopolysaccarhide at a concentration of no greater than about 10.0 endotoxin units per milliliter. The present invention also provides methods of making and methods of using such compositions.Type: ApplicationFiled: January 31, 2012Publication date: August 2, 2012Applicant: Epitopix, LLCInventors: Daryll A. Emery, Darren E. Straub
-
Publication number: 20120189640Abstract: Disclosed are compositions and methods related to variable lymphocyte receptors (VLRs). More particularly, disclosed are a variety of antigen specific polypeptides, including soluble, monoclonal, and multivalent forms, as well as methods of using the polypeptides, antibodies that bind the antigen specific polypeptides, and nucleic acids, vectors and expression systems that encode the polypeptides. Antigen specific polypeptides that selectively bind pathogens, like anthrax, and carbohydrates, like blood group determinants, are specifically disclosed.Type: ApplicationFiled: July 27, 2007Publication date: July 26, 2012Applicant: THE UAB RESEARCH FOUNDATIONInventors: Max D. Cooper, Brantley R. Herrin, Matthew N. Alder
-
Publication number: 20120177663Abstract: This invention provides antibodies that specifically bind to and neutralize botulinum neurotoxin type A (BoNT/A) and the epitopes bound by those antibodies. The antibodies and derivatives thereof and/or other antibodies that specifically bind to the neutralizing epitopes provided herein can be used to neutralize botulinum neurotoxin and are therefore also useful in the treatment of botulism.Type: ApplicationFiled: July 1, 2011Publication date: July 12, 2012Inventors: James D. Marks, Peter Amersdorfer, Isin Geren, Jianlong Lou, Ali Razai, Maria Consuelo Garcia
-
Publication number: 20120177650Abstract: A method and composition for treating enteric pathogen infections in animals suffering from such infections or displaying diseases or conditions consistent with such infections or for preventing or reducing the likelihood of enteric pathogen infections in animals at risk for developing such infections.Type: ApplicationFiled: September 22, 2010Publication date: July 12, 2012Inventor: Thomas Julius Borody
-
Publication number: 20120164156Abstract: Disclosed herein is a method of inducing an immunological response in a subject which comprises administering an immunogenic amount of a purified fusion protein comprising all or part of F1 antigen of Yersinia pestis fused to the amino terminus of all of V antigen of Yersinia pestis, Yersinia enterocolitica, or Yersinia pseudotuberculosis to the subject.Type: ApplicationFiled: May 6, 2008Publication date: June 28, 2012Inventors: David G. Heath, Arthur M. Friedlander, George W. Anderson, JR., Susan L. Welkos
-
Publication number: 20120156196Abstract: The present invention provides an antibody which binds to B. anthracis with toxin, formulations for administration of such antibodies intramuscularly, and methods of administering such antibodies prophylactically or therapeutically.Type: ApplicationFiled: March 30, 2011Publication date: June 21, 2012Applicant: ELUSYS THERAPEUTICS, INC.Inventor: Leslie S. CASEY
-
Patent number: 8197816Abstract: The present invention relates to a human monoclonal antibody specific for the serotype IATS O11 of P. aeruginosa, a hybridoma producing it, nucleic acids encoding it, and host cells transfected therewith. Further, the present invention relates to methods for producing said monoclonal antibody. In addition, the present invention relates to pharmaceutical compositions comprising at least one antibody or at least one nucleic acid encoding said antibody.Type: GrantFiled: February 13, 2006Date of Patent: June 12, 2012Assignee: Kenta Biotech AGInventors: Alois B. Lang, Michael P. Horn, Martin A. Imboden, Adrian Zuercher
-
Patent number: 8192720Abstract: Compositions and methods for the detection, prevention, or treatment of anthrax or other infectious diseases. In one aspect, the present invention provides methods for immunizing humans or animals against Bacillus anthracis or other capsulated pathogens. The methods include administering a capsular polypeptide of a pathogen of interest and a CD40 agonist to a human or animal. The capsular polypeptide or the CD40 agonist is administered in such an amount or frequency that an immunoprotective response can be elicited in the human or animal against the pathogen of interest. In another aspect, the present invention provides methods of using passive immunization with anti-capsular polypeptide antibodies to prevent or treat infections caused by Bacillus anthracis or other pathogens. In yet another aspect, the present invention provides methods useful for diagnosis of anthrax by detection of capsular polypeptide in serum or other biological samples.Type: GrantFiled: February 5, 2010Date of Patent: June 5, 2012Assignee: Board of Regents of the Nevada System of Higher Education, on behalf of the University of Nevada, RenoInventors: Thomas Kozel, William Murphy, Suzanne Brandt, Bruce R. Blazar, Julie A. Lovchik, Peter Thorkildson, Ann Percival, C. Richard Lyons
-
Publication number: 20120134999Abstract: The present invention features peptides of a PorB polypeptide, which PorB peptides are useful in production of antibodies that bind the full-length PorB polypeptide and as a therapeutic agent. In specific embodiments the invention features a composition comprising one or more PorB peptides (other than a full-length PorB polypeptide), which peptides contain at least one epitope that can elicit Chlamydia-neutralizing antibodies. The invention also features methods for induction of a protective immune response against infection by Chlamydia and Chlamydiophila.Type: ApplicationFiled: September 7, 2011Publication date: May 31, 2012Inventors: Richard S. Stephens, Diane Kawa
-
Publication number: 20120114656Abstract: In this application are described fully human monoclonal antibodies which specifically recognize F1 or V antigen of Y. pestis and epitopes recognized by these monoclonal antibodies. Also provided are mixtures of antibodies of the present invention, as well as methods of using individual antibodies or mixtures thereof for the detection, prevention, and/or therapeutical treatment of plague infections in vitro and in vivo.Type: ApplicationFiled: April 8, 2010Publication date: May 10, 2012Inventors: Kei Amemiya, Dimiter S. Dimitrov, Xiaodong Xiao
-
Patent number: 8173130Abstract: The present invention provides a novel class of monoclonal antibodies which have a high affinity, broad spectrum neutralizing reactivity to flagellin from various Gram-negative bacteria including, but not limited to, E. coli, Salmonella, Serratia, Proteus, Enterobacter, Citrobacter, Campylobacter and Pseudomonas. The present invention further provides methods of treating inflammatory bowel disease (IBD) and methods of treating enterobacterial infections using anti-flagellin antibodies in humans, other animals and birds.Type: GrantFiled: September 5, 2008Date of Patent: May 8, 2012Assignee: Inotek Pharmaceuticals CorporationInventors: Andrew L. Salzman, Kanneganti Murthy
-
Patent number: 8148499Abstract: The invention relates to a vaccine for the treatment of disease caused by Neisseria, the vaccine comprising one or more immunogenic components for Neisseria serogroups, as well as antibodies to the immunogenic components and methods of preventing and treating Neisseria infections. The immunogens are based on elements of the inner core lipopolysaccharide.Type: GrantFiled: February 14, 2011Date of Patent: April 3, 2012Assignee: Isis Innovation Ltd.Inventors: Joyce Susan Plested, Michael Paul Jennings, Margaret Ann Jaqueline Gidney, Andrew David Cox, James Clare Richards, Edward Richard Moxon
-
Patent number: 8142780Abstract: A pharmaceutical composition includes a purified antibody and a pharmaceutically acceptable carrier. The antibody can be a monoclonal antibody having both an antigen-binding portion that binds at least one bacterial antigen and a constant region that does not bind staphylococcal protein A.Type: GrantFiled: August 31, 2010Date of Patent: March 27, 2012Assignee: STROX Biopharmaceuticals, LLCInventor: Stanley Arthur Kim
-
Patent number: 8137679Abstract: A microbial adherence inhibitor specific to lactic acid producing microorganisms, in the form of fowl egg antibodies is disclosed, along with the method of making it and methods of using it. The inhibitor functions by substantially preventing the attachment or adherence of colony-forming immunogens in the fermentators. The inhibitor is made by inoculating female birds with the immunogen, allowing time for an immune response in the female bird and then harvesting the eggs that contain antibodies to the immunogen. The egg contents can be dried or used as a liquid and added to the media in the fermentators. Dependent upon the particular immunogen with which the female bird is inoculated, the egg antibody will specifically bind to the specific immunogen. When bacteria such as Lactobacillus spp. infect fermentation systems, they will further reduce alcohol conversion efficiency. Colony forming immunogens such as Lactobacillus spp.Type: GrantFiled: January 12, 2009Date of Patent: March 20, 2012Assignee: Camas IncorporatedInventors: Peter Nash, Bradley M. Mitteness
-
Patent number: 8128941Abstract: Systems, methods, and compositions for a diagnostic method for detecting TB in non-human primates that is easy to use, sensitive, and specific. The method utilizes recombinant mycobacterial antigens, such as polyfusion proteins. The method utilizes an antigen-antibody-antigen arrangement to detect TB infection in nonhuman primates. The method can detect IgM antibodies to TB, in addition to IgG antibodies, providing ability to detect TB earlier in nonhuman primate TB infection as compared to conventional TB tests.Type: GrantFiled: August 26, 2005Date of Patent: March 6, 2012Assignee: Chembio Diagnostic Systems, Inc.Inventors: Konstantin Lyashchenko, Javanbakhsh Esfandiari, Candace McCombs
-
Publication number: 20120045457Abstract: The present invention relates to isolated nucleic acid molecules which encode an antigen from a nontypable Haemophilus influenzae (H. influenzae) species, a vector which comprises such nucleic acid molecule, and a host cell comprising such vector. Furthermore, the invention provides antigens from a nontypable Haemophilus influenzae species, as well as fragments and variants thereof, a process for producing such antigens, and a process for producing a cell, which expresses such antigen. More specifically such antigens are produced by or associated with bacterial infections caused by nontypable Haemophilus influenzae.Type: ApplicationFiled: February 15, 2010Publication date: February 23, 2012Applicant: INTERCELL AGInventors: Alexander Von Gabain, Eszter Nagy, Andreas Meinke, Sanja Selak, Markus Hanner, Margarita Smidt, Michaela Weissgram, Birgit Noiges, Stefan Seidel, Julia Bacher, Christina Satke, Wolfgang Schueler, Martin Oleksiewicz
-
Publication number: 20120039984Abstract: A glycolipopeptide comprising a carbohydrate component, a peptide component and a lipid component, for use as a therapeutic or prophylactic vaccine. Also provided are monoclonal and polyclonal antibodies that recognize the glycolipopeptide of the invention, as well as uses thereof.Type: ApplicationFiled: July 2, 2009Publication date: February 16, 2012Applicant: University of Georgia Research Foundation, Inc.Inventors: Geert-Jan Boons, Therese Buskas, Alex J. Harvey, Sampat Ingale, Margaretha Wolfert, Robert Lance Wells
-
Publication number: 20120027771Abstract: The present invention discloses compositions and methods for treating, preventing and/or monitoring viral, bacterial, eukaryotic protist and/or fungal infections. In some embodiments, these compositions and methods involve human polyclonal antibodies affinity purified from human blood using certain viral, bacterial, eukaryotic protist and/or fungal antigens as described herein. Methods of making the antigenic preparations and the affinity-purified human polyclonal antibodies for passive immunization are also provided.Type: ApplicationFiled: April 12, 2011Publication date: February 2, 2012Inventor: THOMAS L. CANTOR
-
Patent number: 8101367Abstract: Disclosed are antibodies that bind to the antigenic proteins GroES, RpIL, GroEL, SodB, UbiG, the ABC transporter, and an expressed antigenic protein of unknown function (the “BepA” protein) of Bartonella henselae, and use of these antigenic proteins in immunoassays in order to determine whether a sample from a subject contains one or more of these antibodies. Presence of such an antibody in the subject indicates that the subject is or was infected with Bartonella henselae, or indicates that the subject has an increased likelihood of being infected presently or in the past with Bartonella henselae. Also disclosed are kits for performing immunoassays, wherein each kit contains one or more of these antigenic proteins and also contains the reagents necessary for conducting an immunoassay.Type: GrantFiled: November 24, 2009Date of Patent: January 24, 2012Assignee: Medical Diagnostic Laboratories, LLCInventors: Tera L. McCool, Chien Chang Loa, Eli Mordechai, Martin E. Adelson
-
Patent number: 8093360Abstract: The present invention provides an antibody which binds to B. anthracis with toxin, formulations for administration of such antibodies intramuscularly, and methods of administering such antibodies prophylactically or therapeutically.Type: GrantFiled: September 28, 2007Date of Patent: January 10, 2012Assignee: Elusys Therapeutics, Inc.Inventor: Leslie S. Casey
-
Publication number: 20110305704Abstract: Methods for preventing IBS, reducing the likelihood of developing IBS and/or treating IBS by administering COT inhibitors and/or COT neutralizers to a subject in need thereof are described. Methods of eliciting a specific immune response and methods of vaccinating a subject to prevent IBS or to reduce the likelihood of developing or having IBS are also provided. Methods of diagnosing IBS by detecting the presence or absence of COT or a COT marker in a subject are described.Type: ApplicationFiled: February 11, 2010Publication date: December 15, 2011Applicant: CEDARS-SINAI MEDICAL CENTERInventors: Mark Pimentel, Christopher Chang
-
Patent number: 8071100Abstract: The present invention relates to monoclonal antibodies that bind or neutralize anthrax lethal factor (LF), edema factor (EF), and/or protective antigen (PA). The invention provides such antibodies, fragments of such antibodies retaining anthrax toxin-binding ability, fully human or humanized antibodies retaining anthrax toxin-binding ability, and pharmaceutical compositions including such antibodies. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. Additionally, the invention provides for prophylactic, therapeutic, and diagnostic methods employing the antibodies and nucleic acids of the invention.Type: GrantFiled: February 21, 2008Date of Patent: December 6, 2011Assignee: The Unites States of America as represented by the Secretary of Department of Health and Human ServicesInventors: Zhaochun Chen, Robert H. Purcell, Suzanne U. Emerson, Stephen H. Leppla, Mahtab Moayeri
-
Publication number: 20110296545Abstract: Particular aspects show that the signal peptide remains intact on the mature CD18 molecule on ruminant leukocytes rendering these cells susceptible to cytolysis by Lkt. Comparative amino acid sequence analysis of the signal peptide of CD18 of eight ruminants and five non-ruminants revealed that the ruminant CD18 signal peptides contain ‘cleavage-inhibiting’ glutamine (Q), compared to ‘cleavage-conducive’ glycine in non-ruminants, at position ?5 relative to the cleavage site. Mutagenesis of Q at position ?5 of the bovine CD18 signal peptide to G resulted in the abrogation of Lkt-mediated cytolysis of transfectants expressing bovine CD18 carrying the Q(?5)G mutation. Provided is novel technology to clone cattle and other ruminants expressing CD18 without the signal peptide on their leukocytes, providing ruminants that are less susceptible to M. haemolytica. Methods for treating conditions and/or diseases associated with M. haemolytica (e.g.Type: ApplicationFiled: February 2, 2010Publication date: December 1, 2011Applicant: Washington State UniversityInventors: Subramaniam Srikumaran, Sudarvili Shanthalingam
-
Patent number: 8057797Abstract: The disclosed technology provides an enriched antibody population, highly specific for an antigen of a surface polysaccharide, from a mycobacterium. In a related embodiment, the antibody is enriched by having been raised in an environment that maintains antigenically active antigen. These antibodies may be used in an immunoreactive environment for detecting the presence of a mycobacterial infection in a sample from a subject.Type: GrantFiled: October 19, 2009Date of Patent: November 15, 2011Assignee: Chemogen, Inc.Inventors: Vladimir A. Koulchin, Elena V. Molokova, Jill L. Kerrick
-
Publication number: 20110236306Abstract: This invention provides isolated or recombinant polypeptides that are useful to vaccinate individuals suffering from chronic/recurrent biofilm disease or as a therapeutic for those with an existing infection. The individual's immune system will then naturally generate antibodies which prevent or clear these bacteria from the host by interfering with the construction and or maintenance of a functional protective biofilm. Alternatively, antibodies to the polypeptides can be administered to treat or prevent infection. Bacteria that cannot form functional biofilms are more readily cleared by the remainder of the host's immune system.Type: ApplicationFiled: March 28, 2011Publication date: September 29, 2011Inventors: STEVEN D. GOODMAN, LAUREN O. BAKALETZ
-
Publication number: 20110236399Abstract: This invention is directed to compositions and methods for treating (e.g., prophylactically and/or therapeutically) infection in a preterm infant. In particular, the invention provides anti-lipoteichoic acid (LTA) antibody compositions and methods of administering the same to a preterm infant (e.g., a low birth weight preterm infant (e.g., a very low birth weight preterm infant)) under conditions to establish anti-LTA antibody serum concentrations effective to kill and/or prevent growth of bacteria (e.g., Staphylococci). Compositions and methods of the invention find use in, among other things, clinical (e.g. therapeutic and preventative medicine) and research applications.Type: ApplicationFiled: March 29, 2011Publication date: September 29, 2011Applicant: BIOSYNEXUS INCORPORATEDInventors: James J. Mond, Irwin Scher, John F. Kokai-Kun
-
Patent number: 8025880Abstract: The present invention relates to materials and methods for prevention, treatment and diagnosing of infections caused by Helicobacter pylori (H. pylori). More specifically the present invention relates to new specific variable antibody regions, derivatives thereof and the fully human immunoglobulin, Abba3, which exhibit specific activity to the BabA antigen, expressed by H. pylori, methods for the production of said immunoglobulins, their isolation and use, for example in detection of disease causing H. pylori. The present invention also relates to immunization therapies, i.e. passive vaccination for the treatment and prevention of pathologic infections caused by H. pylori strains.Type: GrantFiled: February 26, 2008Date of Patent: September 27, 2011Assignee: Helicure ABInventors: Thomas Borén, Lennart Hammarström
-
Patent number: 8021663Abstract: The present invention relates to the field of animal health and in particular to Lawsonia intracellularis. In particular, the invention relates to a method of diagnosing Lawsonia intracellularis infection and a diagnostic test kit using Lawsonia intracellularis-specific antibodies. The invention also relates to the use of the method or test kit for diagnosing Lawsonia intracellularis infections.Type: GrantFiled: April 28, 2011Date of Patent: September 20, 2011Assignee: Boehringer Ingelheim Vetmedica GmbHInventor: Malik Merza
-
Patent number: 8017134Abstract: A single polypeptide is provided which comprises first and second domains. The first domain enables the polypeptide to cleave one or more vesicle or plasma-membrane associated proteins essential to exocytosis, and the second domain enables the polypeptide to be translocated into a target cell or increases the solubility of the polypeptide, or both. The polypeptide thus combines useful properties of a clostridial toxin, such as a botulinum or tetanus toxin, without the toxicity associated with the natural molecule. The polypeptide can also contain a third domain that targets it to a specific cell, rendering the polypeptide useful in inhibition of exocytosis in target cells. Fusion proteins comprising the polypeptide, nucleic acids encoding the polypeptide and methods of making the polypeptide are also provided. Controlled activation of the polypeptide is possible and the polypeptide can be incorporated into vaccines and toxin assays.Type: GrantFiled: January 27, 2009Date of Patent: September 13, 2011Assignees: Syntaxin Limited, The Health Protection AgencyInventors: Clifford Charles Shone, Conrad Padraig Quinn, Keith Alan Foster, John Chaddock, Philip Marks, John Sutton, Patrick Stancombe, Jonathan Wayne
-
Patent number: 8012491Abstract: A single polypeptide is provided which comprises first and second domains. The first domain enables the polypeptide to cleave one or more vesicle or plasma-membrane associated proteins essential to exocytosis, and the second domain enables the polypeptide to be translocated into a target cell or increases the solubility of the polypeptide, or both. The polypeptide thus combines useful properties of a clostridial toxin, such as a botulinum or tetanus toxin, without the toxicity associated with the natural molecule. The polypeptide can also contain a third domain that targets it to a specific cell, rendering the polypeptide useful in inhibition of exocytosis in target cells. Fusion proteins comprising the polypeptide, nucleic acids encoding the polypeptide and methods of making the polypeptide are also provided. Controlled activation of the polypeptide is possible and the polypeptide can be incorporated into vaccines and toxin assays.Type: GrantFiled: February 11, 2009Date of Patent: September 6, 2011Assignees: Syntaxin, Ltd., Health Protection AgencyInventors: Clifford Charles Shone, Conrad Padraig Quinn, Keith Alan Foster, John Chaddock, Philip Marks, J. Mark Sutton, Patrick Stancombe, Jonathan Wayne
-
Patent number: 8007803Abstract: The present invention provides isolated polypeptides isolatable from a Staphylococcus spp. Also provided by the present invention are compositions that include one or more of the polypeptides, and methods for making and methods for using the polypeptides.Type: GrantFiled: September 11, 2006Date of Patent: August 30, 2011Assignee: Epitopix, LLCInventors: Daryll A. Emery, Darren E. Straub, Laura Wonderling, Lisa L. Herron Olson
-
Patent number: 8007802Abstract: The present invention relates to the field of animal health and in particular to Lawsonia intracellularis. In particular, the invention relates to a method of diagnosing Lawsonia intracellularis infection and a diagnostic test kit using Lawsonia intracellularis-specific antibodies. The invention also relates to the use of the method or test kit for diagnosing Lawsonia intracellularis infections.Type: GrantFiled: April 28, 2011Date of Patent: August 30, 2011Assignee: Boehringer Ingelheim Vetmedica GmbHInventor: Malik Merza
-
Patent number: 8007801Abstract: The present invention relates to the field of animal health and in particular to Lawsonia intracellularis. In particular, the invention relates to a method of diagnosing Lawsonia intracellularis infection and a diagnostic test kit using Lawsonia intracellularis-specific antibodies. The invention also relates to the use of the method or test kit for diagnosing Lawsonia intracellularis infections.Type: GrantFiled: April 28, 2011Date of Patent: August 30, 2011Assignee: Boehringer Ingelheim Vetmedica GmbHInventor: Malik Merza
-
Publication number: 20110206693Abstract: Embodiments herein provide for lysine riboswitches and analogs thereof, and methods for using the same. In certain embodiments, test compounds are identified that associate with lysine riboswitches. In other embodiments, test compounds found to associate with lysine can be used to increase or decrease gene expression of Gram-negative bacterial organisms.Type: ApplicationFiled: April 14, 2009Publication date: August 25, 2011Inventors: Robert Batey, Andrew Garst
-
Publication number: 20110206685Abstract: Isolation of an iron regulated, nme-gene operon (designated sbn) from Staphylococcus aureus (RN6390), responsible for the biosynthesis of staphylobactm, a novel S. aureus siderophore Methods for treating or preventing a disease or condition caused by S. aureus infection, as well as methods for identifying agents that inhibit the biosynthesis of staphylobactm or inhibit the expression of genes in said sbn operon are further disclosed.Type: ApplicationFiled: September 8, 2005Publication date: August 25, 2011Inventors: David E. Heinrichs, Suzanne Dale
-
Publication number: 20110206692Abstract: The invention relates to isolated or purified bacterial adhesin conformers, preferably with improved stability and/or immunogenicity. In a preferred aspect, the invention comprises an isolated bacterial adhesin conformer F. Also provided are methods of isolation and/or separation of such adhesin conformers. The compositions may include one or more of the immunogenic polypeptides either alone or with other antigenic components. For example, the immunogenic polypeptides may be combined with other bacterial antigens to provide therapeutic compositions with broader range.Type: ApplicationFiled: June 11, 2007Publication date: August 25, 2011Inventors: Domenico Maione, Nathalie Norais, Guido Grandi, Vincenzo Nardi-Dei
-
Patent number: 8003107Abstract: The present invention relates to the field of animal health and in particular to Lawsonia intracellularis. In particular, the invention relates to a method of diagnosing Lawsonia intracellularis infection and a diagnostic test kit using Lawsonia intracellularis-specific antibodies. The invention also relates to the use of the method or test kit for diagnosing Lawsonia intracellularis infections.Type: GrantFiled: April 28, 2011Date of Patent: August 23, 2011Assignee: Boehringer Ingelheim Vetmedica GmbHInventor: Malik Merza
-
Publication number: 20110200614Abstract: The present invention is directed to diagnostic tools and therapies using antibodies to Bacillus anthracis. Specifically, the present invention is directed to a B. anthracis-specific monoclonal antibody that binds to the EA1 antigen (corresponding to the eag gene) of the S-layer (surface layer) of spores. This monoclonal antibody may be used in a variety of applications, including to specifically detect and diagnose B. anthracis. Preferably, antibodies are monoclonal and bind to a surface protein, such as EA1 protein, on the spores of B. anthracis, and not to spores of either B. cereus or B. thuringiensis. Antibodies can be incorporated into detection kits using, for example, colloidal particle based lateral flow detection system. Such detection kits can distinguish anthrax spores from non-pathogenic varieties of spores. In addition, the invention is directed to B.Type: ApplicationFiled: November 16, 2009Publication date: August 18, 2011Inventors: Beverly Lynn Mangold, Jennifer Lynn Aldrich, Thomas W. O'Brien
-
Publication number: 20110200616Abstract: The present invention provides compositions including siderophore receptor polypeptides and porins from gram negative microbes, and preferably, lipopolysaccarhide at a concentration of no greater than about 10.0 endotoxin units per milliliter. The present invention also provides methods of making and methods of using such compositions.Type: ApplicationFiled: April 21, 2011Publication date: August 18, 2011Applicant: Epitopix, LLCInventors: Daryll A. Emery, Darren E. Straub, Donavan E. Zammert, Gayla K. Kallevig
-
Publication number: 20110195075Abstract: Methods for enhancing opsonophagocytosis of a pathogen of interest are disclosed. The disclosed methods include administering to a subject an isolated P4 peptide, which including the amino acid sequence set forth as SEQ ID NO: 1 and optionally an isolated opsonic antibody or a fragment thereof that specifically binds to an antigen present of the surface of the pathogen of interest. In some examples isolated complement protein or a fragment thereof (for example, a C3a, C3b, iC3b, C3d, C4b, or C5a fragment of a complement protein) is also administering. Compositions contain isolated P4 peptide and one or more isolated opsonic antibodies or a fragment thereof that specifically binds to an antigen present of the surface of a pathogen of interest are also disclosed. In some examples, the compositions also isolated complement protein or fragment thereof, such as one or more of C3a, C3b, iC3b, C3d, C4b, or C5a.Type: ApplicationFiled: July 31, 2009Publication date: August 11, 2011Inventors: Edwin W. Ades, Gowrisankar Rajam, Sandra Steiner, George M. Carlone, Nikkol Melnick, Jacquelyn S. Sampson, Joseph E. Martinez, Julie M. Skinner
-
Patent number: 7993649Abstract: The present invention relates to the field of animal health and in particular to Lawsonia intracellularis. In particular, the invention relates to a method of diagnosing Lawsonia intracellularis infection and a diagnostic test kit using Lawsonia intracellularis-specific antibodies. The invention also relates to the use of the method or test kit for diagnosing Lawsonia intracellularis infections.Type: GrantFiled: April 28, 2011Date of Patent: August 9, 2011Assignee: Boehringer Ingelheim Vetmedica GmbHInventor: Malik Merza
-
Publication number: 20110189197Abstract: The present invention relates to antibodies and related molecules that specifically bind to protective antigen of Bacillus anthracis (PA). Such antibodies have uses, for example, in the prevention and treatment of anthrax and anthrax toxin poisoning. The invention also relates to nucleic acid molecules encoding anti-PA antibodies, vectors and host cells containing these nucleic acids, and methods for producing the same.Type: ApplicationFiled: February 16, 2011Publication date: August 4, 2011Applicant: Human Genome Sciences, Inc.Inventors: Craig A. Rosen, Michael W. Laird, Reiner L. Gentz
-
Publication number: 20110189196Abstract: The present invention relates to an isolated antigen from Streptomyces coelicolor that is useful for developing, inter alia, vaccines against pathogenic bacteria of humans and animals. The present invention also relates to vaccines and antibodies developed using the isolated antigen. The present invention also relates to methods of using the antigen, vaccines, and antibodies of the present invention to detect, treat, and prevent infection and diseases associated with pathogenic bacteria.Type: ApplicationFiled: June 8, 2009Publication date: August 4, 2011Applicant: SYRACUSE UNIVERSITY TECHNOLOGY TRANSFER AND INDUSTRIAL DEVELOPMENT OFFICEInventors: Robert P. Doyle, Joshua J. Lensbouer